Search results for "platelet count"

showing 10 items of 66 documents

Platelet-activating factor type activity in plasma from patients with septicemia and other diseases

1991

The purpose of the present study was to determine whether increased levels of platelet-activating factor (PAF) type activity can be detected in plasma from patients with septicemia and other diseases. A level of PAF below 0.5 ng/mL of plasma was considered normal. We found that plasma from a patient with adverse anaphylactoidic reaction to intravenous analgetics contained 2.1 ng PAF/mL. In seven patients with septicemia, including urosepsis, endocarditis and peritonitis, and with positive blood culture, increased plasma PAF levels (1-20 ng PAF/mL) were observed. Other patients with clinical indications of septicemia had negative blood cultures and/or increased levels of C-reactive protein (…

AdultBlood PlateletsMalemedicine.medical_specialtyPlatelet AggregationClinical chemistryPeritonitisBacteremiaBiochemistrySepsischemistry.chemical_compoundReference ValuesInternal medicinemedicineAnimalsHumansPlateletPlatelet Activating FactorPlatelet-activating factorPlatelet CountSeptic shockbusiness.industryOrganic ChemistryAntagonistAzepinesCell BiologyMiddle AgedTriazolesrespiratory systemmedicine.diseaseThrombocytopenic purpuraC-Reactive ProteinEndocrinologyPurpura ThrombocytopenicchemistryImmunologyFemalelipids (amino acids peptides and proteins)RabbitsbusinessLipids
researchProduct

Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count.

2002

Abstract Introduction: Platelet-rich plasma contains autologous thrombocyte growth factors and might be promising for acceleration of dentoalveolar bone regeneration. In this study, it was analysed for platelet counts and growth factor concentrations. Material and method: Platelet-rich plasma was isolated by discontinuous cell separation from 158 healthy men and 55 women aged 17–62 years. One hundred and fifteen specimens (stratified for age and gender of the donor) were analysed for growth factor concentrations and platelet count. Results: The platelet count in platelet-rich plasma (1,407,640±320,100/μl) was 5 times higher than in donor blood (266,040±60,530/μl). Platelet-derived growth fa…

AdultBlood PlateletsMalemedicine.medical_specialtyPlatelet-derived growth factorAdolescentmedicine.medical_treatmentBecaplerminPlateletpheresisBlood DonorsEnzyme-Linked Immunosorbent AssayTransforming Growth Factor beta1chemistry.chemical_compoundTransforming Growth Factor beta2Sex FactorsTransforming Growth Factor betaInternal medicineMedicineHumansPlateletInsulin-Like Growth Factor IBone regenerationGrowth SubstancesPlatelet-Derived Growth Factorbiologybusiness.industryPlatelet CountGrowth factorPlateletpheresisAge FactorsProto-Oncogene Proteins c-sisMiddle AgedEndocrinologyOtorhinolaryngologychemistryPlatelet-rich plasmabiology.proteinSurgeryFemaleOral SurgerybusinessGelsPlatelet-derived growth factor receptorTransforming growth factorJournal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
researchProduct

Effect of training status on the changes in platelet parameters induced by short–duration exhaustive exercise

2015

It is now well known that hemostasis is directly involved in the benefits induced by physical activity. It has recently been shown that the baseline mean platelet volume (MPV) may be a predictor of endurance performance. We aimed to explore whether platelet parameters are associated with VO2max as well as running duration and speed in a short-duration exhaustive exercise test. Thirty healthy male subjects (10 sedentary and 20 trained) performed an incremental running test until exhaustion. MPV, platelet distribution width (PDW), platelet (Plt) count, and plateletcrit (Pct) were determined before exercise, immediately after exercise and after 30′ recovery. Training status did not produce any…

AdultBlood PlateletsMalemedicine.medical_specialtyVital CapacityPhysical activityRunningOxygen ConsumptionInternal medicineMedicineHumansPlateletPlatelet activationMean platelet volumeShort durationExercisebusiness.industryPlatelet CountPlatelet Distribution WidthHematologyGeneral MedicinePlatelet ActivationTest durationAthletesHemostasisPhysical therapyCardiologyPhysical EnduranceSedentary BehaviorbusinessMean Platelet Volume
researchProduct

Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy.

1989

Abstract The effect of recombinant human granulocyte colony-stimulating factor (G-CSF) on hematologic parameters was evaluated in a phase I clinical study in 18 patients with advanced malignancy. G-CSF was administered once daily as a 30-minute infusion for 14 days; three patients each were treated at increasing dose levels of 1, 3, 10, 30, and 60 micrograms kg-1 day-1. A transient decrease in neutrophil and monocyte counts was observed immediately after the G-CSF infusion, followed by a dose-dependent increase of up to 15-fold. G-CSF-induced neutrophils exhibited an increased O2- radical production, and serum levels of enzymes related to granulocyte turnover, including lysozyme and elastas…

AdultBlood Plateletsmedicine.medical_specialtySide effectImmunologyAntineoplastic AgentsPlatelet Membrane GlycoproteinsGranulocyteMalignancyBiochemistryLeukocyte CountColony-Stimulating FactorsSuperoxidesInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansPlateletBone painAgedbusiness.industryPlatelet CountMonocyteElastaseReceptors Interleukin-2Cell BiologyHematologyMiddle Agedmedicine.diseaseRecombinant ProteinsGranulocyte colony-stimulating factorHematopoiesisEndocrinologymedicine.anatomical_structureImmunologyDrug Evaluationmedicine.symptombusinessBlood
researchProduct

Blood rheology during chemotherapy in patients with ovarian cancer.

1998

The use of platinum based chemotherapy in ovarian malignancy and other cancer types is known to be associated with deep vein thrombosis. In a prospective study of 47 patients with ovarian cancer of International Federation of Gynecology and Obstetrics stage Ib-IV, serial rheological parameters were determined (plasma viscosity, red blood cell aggregation under conditions of stasis and low shear) in addition to hemoglobin, hematocrit, leukocytes, platelets, and fibrinogen. At the same time the incidence of deep vein thrombosis was recorded before, during six cycles of first line cisplatinum/epirubicin/cyclophosphamide chemotherapy, and 2 months thereafter (two-months check-up). Only six pati…

AdultErythrocyte Aggregationmedicine.medical_specialtymedicine.drug_classDeep veinBlood viscosityVenographyLow molecular weight heparinAntineoplastic AgentsHematocritGastroenterologyHemoglobinsLeukocyte CountInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesVeinCyclophosphamideAgedEpirubicinOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryPlatelet CountFibrinogenHematologyHeparin Low-Molecular-WeightMiddle AgedThrombophlebitismedicine.diseaseBlood ViscosityThrombosisSurgerymedicine.anatomical_structureHematocritHemorheologyFemaleCisplatinbusinessEpirubicinmedicine.drugThrombosis research
researchProduct

Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection

2010

Historically, liver biopsy (LB) was the sole method to evaluate the severity of hepatic fibrosis in patients with chronic hepatitis C infection. However, LB is expensive and associated with a risk of severe complications. Therefore, noninvasive tests have been developed to assess the severity of liver fibrosis. The accuracy of Fibroscan (FS) and King's score (KS) was evaluated individually and in combination using liver histology as the reference standard. One hundred and eighty-seven patients were identified who had undergone a biopsy with a diagnosis of chronic hepatitis C virus (HCV) mono-infection (HCV RNA-positive by RT-PCR), attending King's College Hospital (n = 88) or the Royal Free…

AdultLiver CirrhosisMaleKing's scoreHepacivirusPredictive Value of TestsVirologyfibrosis; hepatitis C; King's score; transient elastography; Adult; Alanine Transaminase; Alkaline Phosphatase; Area Under Curve; Aspartate Aminotransferases; Bilirubin; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C Chronic; Histocytochemistry; Humans; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Predictive Value of Tests; Prospective Studies; ROC Curve; gamma-Glutamyltransferase; Hepatology; Infectious Diseases; Virology; Medicine (all)Humansfibrosis hepatitis C King s score transient elastographyAspartate AminotransferasesProspective StudiesChronicHepatologyHistocytochemistryPlatelet CountMedicine (all)fibrosisAlanine TransaminaseBilirubingamma-GlutamyltransferaseHepatitis C ChronicMiddle AgedAlkaline Phosphatasetransient elastographyHepatitis CInfectious DiseasesROC CurveArea Under CurveElasticity Imaging TechniquesFemale
researchProduct

Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.

1989

The in vivo effect of yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) was investigated in 30 patients with advanced malignancy in a phase Ib trial. Patients were treated at four different dose levels (120 to 1,000 micrograms/m2/d) by either daily intravenous (IV) bolus injection or 24-hour continuous infusion. Administration of rh GM-CSF resulted in a broad spectrum of dose- and schedule-dependent hematopoietic effects. Sustained infusion of rh GM-CSF elicited a maximum 17-fold average peak increase of the total WBC count with mainly neutrophils, eosinophils, and monocytes accounting for this rise, and increases in bone marrow cellularity with a…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentMicrogramMalignancyDrug Administration ScheduleLeukocyte CountColony-Stimulating FactorsIn vivoBone MarrowInternal medicineNeoplasmsmedicineHumansPlateletLeukocytosisGrowth SubstancesInfusions IntravenousAgedbusiness.industryPlatelet CountGranulocyte-Macrophage Colony-Stimulating FactorMiddle Agedmedicine.diseaseRecombinant ProteinsHematopoiesisHaematopoiesisEndocrinologyGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureOncologyImmunologyInjections IntravenousDrug EvaluationFemalemedicine.symptombusinessmedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Predictive Scores in Primary Biliary Cirrhosis

2015

GOALS The aim of this study was to assess the long-term outcome of primary biliary cirrhosis (PBC) patients and to test the clinical value of various outcome models, such as the Mayo Risk Score (MRS), in a large single-center cohort in Germany. BACKGROUND PBC is a chronic autoimmune liver disease with a female gender predominance and a peak incidence in the fifth decade of life. PBC is characterized by portal inflammation and immune-mediated destruction of intrahepatic bile ducts in liver histology and the presence of antimitochondrial antibodies in the serum of nearly 95% of patients. In 5% to 20% of patients an overlap syndrome with autoimmune hepatitis (AIH) is diagnosed. Ursodeoxycholic…

AdultMaleCholagogues and Cholereticsmedicine.medical_specialtyPathologyAdolescentmedicine.medical_treatmentIntrahepatic bile ductsAutoimmune hepatitisLiver transplantationSeverity of Illness IndexGastroenterologyYoung AdultLiver diseasePrimary biliary cirrhosisPredictive Value of TestsInternal medicinemedicineHumansAspartate AminotransferasesChildAgedRetrospective StudiesAged 80 and overFramingham Risk ScoreLiver Cirrhosis BiliaryPlatelet Countbusiness.industryUrsodeoxycholic AcidGastroenterologyBilirubinOverlap syndromeMiddle AgedAlkaline PhosphatasePrognosismedicine.diseasedigestive system diseasesUrsodeoxycholic acidLiver TransplantationHepatitis AutoimmuneImmunoglobulin MImmunoglobulin GFemalebusinessFollow-Up Studiesmedicine.drugJournal of Clinical Gastroenterology
researchProduct

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

2011

We have previously identified sole +9, 13q- or 20q-, as 'favorable' and sole +8 or complex karyotype as 'unfavorable' cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients, we describe additional sole abnormalities with favorable (chromosome 1 translocations/duplications) or unfavorable (-7/7q-) prognosis and also show that other sole or two abnormalities that do not include i(17q), -5/5q-, 12p-, inv(3) or 11q23 rearrangement are prognostically aligned with normal karyotype, which is prognostically favorable. These findings were incorporated into a refined two-tired cytogenetic-risk stratification: unfavorable and favorable karyotype. The respective 5-y…

AdultMaleRiskCancer Researchmedicine.medical_specialtyPathologyAdolescentChromosomal translocationmyelofibrosisGastroenterologycytogeneticsDisease-Free SurvivalSettore MED/15 - Malattie Del SangueInternal medicineComplex KaryotypemedicineHumansMyelofibrosisAgedAged 80 and overChromosome AberrationsLeukemiaHematologyPlatelet Countbusiness.industryHazard ratioKaryotypeHematologyMiddle AgedPrognosismedicine.diseaseConfidence intervalkaryotypeOncologyPrimary MyelofibrosisInternational Prognostic Scoring SystemKaryotypingOriginal ArticleFemalemyeloproliferativebusiness
researchProduct

Continuous intravenous infusion of dipyridamole as adjunctive therapy in the treatment of thrombotic thrombocytopenic purpura.

2003

Abstract Thrombotic thrombocytopenic purpura (TTP) is an uncommon hematologic thrombotic disorder characterized by fever, hemorrhagic and neurologic signs. The advent of plasma exchange has dramatically improved the prognosis of this disease, which was once inevitably fatal. However, mortality rates remain significant. Antiplatelet drugs have been widely used in combination with plasma exchange. In this pilot study we investigated the effects of an adjunctive therapy consisting of the continuous, intravenous infusion of dipyridamole, a modality of administration that has not been previously tested in this setting. Sixteen untreated TTP patients, diagnosed consecutively at our clinic, receiv…

AdultMaleTime FactorsCombination therapyThrombotic thrombocytopenic purpuraPilot ProjectsMethylprednisolonelaw.inventionRandomized controlled trialRefractorylawRecurrencemedicineHumansPlateletIn patientProspective StudiesInfusions IntravenousPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryPlatelet CountMortality rateRemission InductionHematologyDipyridamoleMiddle Agedmedicine.diseaseCombined Modality TherapyDipyridamoleTreatment OutcomeAnesthesiaFemalebusinessPlatelet Aggregation Inhibitorsmedicine.drugTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
researchProduct